Rhizopus microsporus as Causative Agent of Mucormycosis in COVID-19 Patient

The pandemic of coronavirus disease (COVID-19) emerged as a fatal infection, especially in immunocompromised patients. Currently, this infection is managed with systemic corticosteroids. Co-infection of CO-VID-19 with opportunistic fungi is increasingly recognized. We describe a case of rhino-cerebr...

Full description

Saved in:
Bibliographic Details
Published inClinical laboratory (Heidelberg) Vol. 68; no. 12
Main Authors Sedaghatalab, Moslem, Nouripour-Sisakht, Sadegh, Cheraghzadeh, Seyed R, Sabz, Gholamabas, Gharaghani, Maral
Format Journal Article
LanguageEnglish
Published Germany 01.12.2022
Subjects
Amphotericin B - therapeutic use
Antifungal Agents - therapeutic use
COVID-19 - complications
Diabetes Mellitus
Humans
Male
Mucormycosis - complications
Mucormycosis - diagnosis
Mucormycosis - microbiology
Rhizopus
Online AccessGet more information

Cover

More Information
Summary:The pandemic of coronavirus disease (COVID-19) emerged as a fatal infection, especially in immunocompromised patients. Currently, this infection is managed with systemic corticosteroids. Co-infection of CO-VID-19 with opportunistic fungi is increasingly recognized. We describe a case of rhino-cerebral mucormycosis 12 days following severe COVID-19 in a diabetic patient. He received 50 mg amphotericin B and surgical debridement. The patient's symptoms improved following medical and surgical intervention. Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis.
ISSN:1433-6510
DOI:10.7754/Clin.Lab.2022.220232